All News

Dapagliflozin substantially slowed the progression of chronic kidney disease (CKD) in patients with immunoglobulin A nephropathy, according to a new study.

Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore Medical Center, and professor of neurology, Albert Einstein College of Medicine, speaks on the efficacy of solriamfetol observed in patients with excessive daytime sleepiness associated with narcolepsy, and which patient groups may best benefit from this therapy.

Findings from a retrospective cohort study revealed that individuals with osteoarthritis are more susceptible to the development of Parkinson disease.

A recent decline in the proportion of adults with diabetes achieving glycemic control may contribute to more diabetes-related health issues and deaths across America.

The debate continues whether or not to go maskless when fully vaccinated; the Delta COVID-19 variant is associated with a 2-fold greater risk of hospitalization; an extra vaccine dose may boost COVID-19 protection in organ transplant recipients.

National Institutes of Health–sponsored research examines the underlying cause of COVID-19–induced diabetes.

These review results were mixed on the use of immunotherapy to treat narcolepsy, with benefits typically being temporary.

Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).

Out-of-pocket (OOP) spending for patients with heart failure with reduced ejection fraction rose in the event of a worsening heart failure event across the 4 phases of Medicare Part D coverage.

Study results show that those with migraine are more likely to develop rheumatoid arthritis (RA) and those with RA are also more likely to have migraine.

A roundup of technology-related research presented at SLEEP 2021.

Experts discuss their research on the impact of sex differences in alcohol use disorder (AUD)-related sleep health.

Previous research has suggested the efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors.

Novavax releases positive phase 3 trial data on its COVID-19 vaccine candidate; data show sharp increase in emergency department visits for attempted suicide; decrease in pediatric inpatient units throughout the country.

Results of a post-hoc analysis underscore the efficacy of the Idiopathic Hypersomnia Severity Scale to measure symptoms of idiopathic hypersomia.

Several studies presented at SLEEP 2021 highlight the negative impact COVID-19 has had on youth sleep health.

Anne Marie Morse, DO, pediatric neurologist and sleep medicine specialist, Geisinger, discusses factors contributing to insufficient screening of obstructive sleep apnea (OSA) in patients with stroke and how a team-based approach fared in expediting diagnosis.

New studies into chimeric antigen receptor (CAR)–engineered natural killer (NK) cells has shown promising results, explained Ulrike Köhl, PhD, MD, professor of immune oncology and director of the Institute for Clinical Immunology at the University of Leipzig in Germany.

Research presented at SLEEP 2021 underscores the important role of sleep for firefighters, soldiers, and flight crew members.

Executives from Merck, Bellus Health, Bayer, and Shionogi highlighted their P2X3 data for chronic cough.

Rajasi Mills, MS, vice president, SleepIQ Health, Sleep Number, speaks on the practical use of Sleep Number 360 smart beds in measuring sleep metrics and leveraging data to identify symptoms characteristic of COVID-19 and other respiratory illnesses.

Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.

High-risk patients with diffuse large B-cell lymphoma (DLBCL) may benefit from being treated with a regimen that adds zanubrutinib and lenalidomide to R-CHOP (a combination of the monoclonal antibody rituximab plus the chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone).

Behavioral cough suppression therapy can be used to help patients with chronic cough manage their cough, prevent a cough, and even trigger their cough less often, explained Laurie Slovarp, PhD, CCC-SLP, associate professor in the School of Speech, Language, Hearing, and Occupational Sciences at University of Montana.

Experts from around the world discussed how to best manage the clinical issues presented by patients with refractory chronic cough, who often spend years trying to find effective relief.

Isabelle Arnulf, MD, PhD, senior neurologist, and professor, Neurology, Sorbonne Universités, Pierre and Marie Curie University, discusses findings of significant improvement observed in patients with idiopathic hypersomnia undergoing lower-sodium oxybate treatment.

An overview of the latest news in Parkinson disease (PD) reported across MJH Life Sciences™.

The novel agents are a result of a greater understanding of the conditions and may modify the diseases’ course and cytoreduction, researchers said.